Àwọn nǹkan bíi mélòó kan ló máa ń pinnu bó ṣe máa wo àrùn jẹjẹrẹ ẹ̀dọ̀fóró, irú àrùn jẹjẹrẹ ẹ̀dọ̀fóró tó, àti bí ìlera aláìsàn náà ṣe rí.
Lára àwọn ìtọ́jú tó wọ́pọ̀ ni:
1. Ìṣẹ́ abẹ: Èyí ló sábà máa ń jẹ́ ìtọ́jú tó dára jù lọ fún àrùn jẹjẹrẹ ẹ̀dọ̀fóró tó ti bẹ̀rẹ̀.
Oníṣẹ́ abẹ náà máa ń yọ kòkòrò náà àti díẹ̀ lára àwọn ẹ̀jẹ̀ tó wà láyìíká rẹ̀ kúrò.
2. Ìtọ́jú Ìmọ́lẹ̀: Wọ́n máa ń lo ìmọ́lẹ̀ tó lágbára gan-an láti pa àwọn sẹ́ẹ̀lì àrùn jẹjẹrẹ, kí wọ́n sì dín àwọn kòkòrò tó wà nínú ara kù.
O le ṣee lo nikan tabi ni apapo pẹlu awọn itọju miiran.
3. Ìtọ́jú nípa oògùn olóró: Ìtọ́jú yìí máa ń lo oògùn láti pa àwọn sẹ́ẹ̀lì àrùn jẹjẹrẹ.
Wọ́n lè fi oògùn náà sínú ẹ̀jẹ̀ tàbí láti ẹnu, wọ́n sì sábà máa ń lò ó pa pọ̀ pẹ̀lú àwọn ìtọ́jú mìíràn.
4. Ìlànà ìtọ́jú tí wọ́n gbé kalẹ̀: Ìlànà ìtọ́jú yìí dá lórí àwọn àbùdá tàbí èròjà protein kan pàtó tó ń mú kí àwọn sẹ́ẹ̀lì àrùn jẹjẹrẹ máa dàgbà, tí wọ́n sì máa wà láàyè.
Wọ́n sábà máa ń lò ó fún àrùn jẹjẹrẹ ẹdọfóró tó ti gbilẹ̀ tàbí tó ti yí padà.
5. Ìtọjú àjẹsára: Ìtọjú yìí máa ń ran ètò àjẹsára lọ́wọ́ láti mọ àwọn sẹ́ẹ̀lì àrùn jẹjẹrẹ, kó sì gbéjà kò wọ́n.
Wọ́n sábà máa ń lò ó fún àrùn jẹjẹrẹ ẹdọfóró tó ti gbilẹ̀ tàbí tó ti yí padà.
6. Ìtọ́jú photodynamic: Ìtọ́jú yìí máa ń lo oògùn tí ìmọ́lẹ̀ máa ń mú ṣiṣẹ́ láti pa àwọn sẹ́ẹ̀lì àrùn jẹjẹrẹ.
Wọ́n sábà máa ń lò ó fún àrùn jẹjẹrẹ ẹdọfóró tó ti wà ní ìbẹ̀rẹ̀.
7. Ìtọ́jú Proton: Èyí jẹ́ irú ìtọ́jú ìmọ́lẹ̀ tí wọ́n fi ń lo àwọn èròjà proton dípò àwọn ìmọ́lẹ̀ X láti fi mú ìmọ́lẹ̀ dé ibi tí kòkòrò náà wà.
Wọ́n sábà máa ń lò ó fún àrùn jẹjẹrẹ ẹdọfóró tó ti wà ní ìbẹ̀rẹ̀.
8. Ìdánwò ìṣègùn: Àwọn aláìsàn lè ní àǹfààní láti kópa nínú ìdánwò ìṣègùn tí wọ́n fi ń dán àwọn ìtọ́jú tuntun tàbí àwọn àpapọ̀ ìtọ́jú wò.
Ó ṣe pàtàkì láti jíròrò àwọn ọ̀nà ìtọ́jú tó dára jù lọ pẹ̀lú ẹgbẹ́ olùtọ́jú ìlera, nítorí pé ètò ìtọ́jú tó dára jù lọ yóò sinmi lórí ipò pàtó tí ẹnì kọ̀ọ̀kan wà.
Chen JH, Wu J, Xu Q: The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. , 4 (): 61.
Furuse K: [Photodynamic therapy of centrally located early-stage lung cancer]. Gan To Kagaku Ryoho. 1996, 23 (1): 27-30.
Gálffy G: [From rare mutations to classical ones, inhibition of signaling pathways in non-small cell lung cancer]. Magy Onkol. 2020, 64 (3): 196-204.
Magalhães M, Alvarez-Lorenzo C, Concheiro A, Figueiras A, Santos AC, Veiga F: RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers. Expert Opin Drug Deliv. 2018, 15 (10): 965-982.
Kataoka M, Fujiwara T, Tanaka N: [Gene therapy for lung cancer]. Nihon Geka Gakkai Zasshi. 2002, 103 (2): 244-9.
Jin C, Yang B: A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient. Case Rep Oncol. , 14 (1): 659-663.
Wang Y, Liu Q, Chen H, You J, Peng B, Cao F, Zhang X, Chen Q, Uzan G, Xu L, Zhang D: Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance. Anticancer Drugs. 2018, 29 (8): 748-755.
Ìyàsímímọ́: ìtọ́jú ìlera
Oju opo wẹẹbu yii ni a pese fun eto-ẹkọ ati awọn idi alaye nikan ati pe ko ṣe agbekalẹ pese imọran iṣoogun tabi awọn iṣẹ ọjọgbọn.
A ò gbọ́dọ̀ lo ìsọfúnni tó wà nínú ìwé náà láti ṣe àyẹ̀wò tàbí láti wo àìsàn tàbí àìsàn kan wò, àwọn tó bá sì ń wá ìmọ̀ràn nípa ìṣègùn fúnra wọn gbọ́dọ̀ bá dókítà tó ní ìwé àṣẹ sọ̀rọ̀.
Jọwọ ṣe akiyesi nẹtiwọọki neural ti o ṣe agbejade awọn idahun si awọn ibeere, jẹ pataki ti ko tọ nigbati o ba de si akoonu nọmba. Fun apẹẹrẹ, nọmba awọn eniyan ti a ṣe ayẹwo pẹlu aisan kan pato.
Nigbagbogbo wa imọran ti dokita rẹ tabi olupese ilera ti o ni oye miiran nipa ipo iṣoogun kan. Maṣe gbagbe imọran iṣoogun ọjọgbọn tabi idaduro ni wiwa rẹ nitori nkan ti o ti ka lori oju opo wẹẹbu yii. Ti o ba ro pe o le ni pajawiri iṣoogun, pe 911 tabi lọ si yara pajawiri ti o sunmọ julọ lẹsẹkẹsẹ. Ko si ibatan dokita-aisan ti a ṣẹda nipasẹ oju opo wẹẹbu yii tabi lilo rẹ. Bẹni BioMedLib tabi awọn oṣiṣẹ rẹ, tabi ẹnikẹni ti o ṣe alabapin si oju opo wẹẹbu yii, ṣe eyikeyi awọn aṣoju, ṣalaye tabi tumọ, pẹlu ọwọ si alaye ti a pese nibi tabi lilo rẹ.
Ìyàsímímọ́: ẹ̀tọ́ ọmọnìyàn
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the DMCA) n pese atunṣe fun awọn onihun aṣẹ-aṣẹ ti o gbagbọ pe ohun elo ti o han lori Intanẹẹti ṣe ilokulo awọn ẹtọ wọn labẹ ofin aṣẹ-aṣẹ AMẸRIKA.
Ti o ba gbagbọ ni igbagbọ to dara pe eyikeyi akoonu tabi ohun elo ti o wa ni asopọ pẹlu oju opo wẹẹbu wa tabi awọn iṣẹ ṣe ilokulo aṣẹ-aṣẹ rẹ, iwọ (tabi aṣoju rẹ) le firanṣẹ akiyesi kan si wa ti o beere pe a yọ akoonu tabi ohun elo naa kuro, tabi idilọwọ iraye si rẹ.
A gbọdọ firanṣẹ awọn iwifunni ni kikọ nipasẹ imeeli (wo abala "Ibaṣepọ" fun adirẹsi imeeli).
DMCA nilo pe akiyesi rẹ ti ilokulo aṣẹ-aṣẹ ti a fi ẹsun kan pẹlu alaye wọnyi: (1) apejuwe ti iṣẹ ti o ni aṣẹ-aṣẹ ti o jẹ koko-ọrọ ti ilokulo ti a fi ẹsun kan; (2) apejuwe ti akoonu ti a fi ẹsun kan ati alaye ti o to lati gba wa laaye lati wa akoonu naa; (3) alaye olubasọrọ fun ọ, pẹlu adirẹsi rẹ, nọmba foonu ati adirẹsi imeeli; (4) alaye nipasẹ rẹ pe o ni igbagbọ rere pe akoonu ni ọna ti o ni ẹsun ti ko ni aṣẹ nipasẹ eni aṣẹ-aṣẹ, tabi aṣoju rẹ, tabi nipasẹ iṣẹ ti ofin eyikeyi;
(5) ìpolongo kan láti ọ̀dọ̀ rẹ, tí o fìdí rẹ̀ múlẹ̀ lábẹ́ ìjìyà ẹ̀rí èké, pé ìsọfúnni tó wà nínú ìkéde náà tọ̀nà àti pé o ní àṣẹ láti mú kí àwọn ẹ̀tọ́ ọmọnìyàn tí wọ́n sọ pé wọ́n ti rú ṣẹ ṣẹ;
ati (6) ibuwọlu ti ara tabi itanna ti ẹni ti o ni aṣẹ tabi eniyan ti o ni aṣẹ lati ṣiṣẹ ni orukọ ẹni ti o ni aṣẹ.
Ti o ko ba ṣafikun gbogbo alaye ti o wa loke le ja si idaduro ti ṣiṣe ẹdun rẹ.
Ìfọ̀rọ̀wérọ̀
Jọwọ fi imeeli ranṣẹ si wa pẹlu eyikeyi ibeere / imọran.
How to treat lung cancer?
The treatment for lung cancer depends on several factors, including the stage of the cancer, the type of lung cancer, and the patient's overall health.
Some common treatment options include:
1. Surgery: This is often the preferred treatment for early-stage lung cancer.
The surgeon removes the tumor and a small portion of healthy tissue around it.
2. Radiation therapy: High-energy radiation is used to kill cancer cells and shrink tumors.
It can be used alone or in combination with other treatments.
3. Chemotherapy: This treatment uses drugs to kill cancer cells.
It can be given intravenously or or orally, and is often used in combination with other treatments.
4. Targeted therapy: This treatment targets specific genes or proteins that contribute to the growth and survival of cancer cells.
It is often used for advanced or metastatic lung cancer.
5. Immunotherapy: This treatment helps the immune system recognize and attack cancer cells.
It is often used for advanced or metastatic lung cancer.
6. Photodynamic therapy: This treatment uses a light-activated drug to kill cancer cells.
It is often used for early-stage lung cancer.
7. Proton therapy: This is a type of radiation therapy that uses protons instead of x-rays to deliver radiation to the tumor.
It is often used for early-stage lung cancer.
8. Clinical trials: Patients may be eligible to participate in clinical trials testing new treatments or combinations of treatments.
It is important to discuss the best treatment options with a healthcare team, as the most effective treatment plan will depend on the individual's specific situation.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
Ní nǹkan bí
BioMedLib nlo awọn kọnputa adaṣe (awọn alugoridimu ẹkọ ẹrọ) lati ṣe agbejade awọn tọkọtaya ibeere ati idahun.
A bẹrẹ pẹlu awọn atẹjade biomedical miliọnu 35 ti PubMed/Medline. Pẹlupẹlu, awọn oju-iwe wẹẹbu ti RefinedWeb.
